Some of the leading pharma companies have released their second-quarter results of 2018:

Amgen reported increased sales in Q2 2018 owing to some of its freshly launched products. Revenue hiked by 4% to $6.1 billion, exceeding forecasts $5.7 billion. CEO Robert Bradway commented that "our two most recently launched products, Aimovig and Parsabiv, are off to a strong start".

Astellas saw elevated first-quarter sales of $3 billion and a profit rise of 28.5% to $491 million in spite of a fall in revenue by 12.3% in Japan on account of NHI price revisions with effect from April and generic rivalry for Micardis in Japan.

AstraZeneca's cancer drugs being the key players in second-quarter revenues of $5.2 billion, caused a jump of 2%. Oncology drug sales went up 44% to $1.4 billion, with Tagrisso witnessing a remarkable rise in revenues of 82% to $422 million.

Bristol-Myers Squibb’s revenue escalated by 11% to $5.7 billion in Q2. Eliquis and Opdivo surpassed analysts’ forecasts generating revenues of $1.7 billion and $1.6 billion jumping up 40% and 36%respectively.

Celgene’s sales jumped 17% to $3.8 billion for Q2 with Revlimid and Pomalyst/Imnovid amplifying revenues by 21% to $2.5 billion and 30% to $507 million respectively.

Eli Lilly saw a revenue hike by 9% to $6.4bn in the Q2 of 2018, compared to $5.8bn in Q2 2017, owing to increased demand for new pharmaceutical products in 2018.

GSK saw pharmaceuticals sales of £4.2 billion in this quarter.

J&J’s pharmaceutical division sales of $10.4 billion jumped 17.6% due to a 42% escalation in oncology drugs sales which included Darzalex that grew 71%, Imbruvica 38%, and Zytiga 63%.

Novartis’ revenue was $13.2 billion (+7%, +5% cc) in Q2, as volume growth of 9% points largely influenced by Innovative Medicines growth.